Yes,  I would hope for ASCO  2014   or  before. Depends upon cohort progression, when MTD is reached, and whether DF and Shapiro want to hold off and publish results in a journal. Then there is the caveat that robust Ph1 results from K (labs showing increased P21/53 activation) would qualify as a "material event" according to the SEC, which must be disclosed within days.

Would love to hear biotech mavens weigh in on this balancing act between medical trial results, sec regulations for material events, and publishing rights.